Source of the article:Moptim;Editor: Bai XiaofeiReprint requirements: Can be reprinted 24 hours after the first publication, source must be acknowledged.
Recently,Shenzhen Certainn Technology Co., Ltd.(Moptim Medical, for short) inThe 39th Asia-Pacific Academy of Ophthalmology (APAO) Congress and the 49th Annual Meeting of the Indonesian Ophthalmologists Association (Perdami)UpHighlighting itsBased on1050nm OCT Technology Ophthalmic Optical Biometer - Colombo IOL, and has gained prominence in the Asia-Pacific ophthalmology technology trend with its unique advantages.
This conference was held inNusa Dua Convention Center, Bali, IndonesiaConvene,As a grand event in the international ophthalmology community, APAO 2024, with the theme "Beyond All Limits," brings together numerous top global ophthalmology experts and researchers to jointly explore cutting-edge knowledge and practical experiences in ophthalmic medicine, driving continuous progress and innovation in the field.
▲Source: Official WeChat Account of the Company
# Colombo IOL Visual Optical Biometer
▲Source: Company Official Website
Colombo IOL Visual Optical BiometerFor the first timeWillFrequency Domain OCT and Optical MeasurementsCombination, winning the China Patent Excellence Award. This product...Designed for adolescent myopia prevention and control,One measurement, multiple optometric parameters obtained；Real-time Visual Measurement，Precise axial fixation confirmation; high-definition OCT images, detecting abnormal fundus structure;Integrated Design`, full parameter measurement, achieving more efficient data management.`The biggest technical advantage of this product lies inComprehensive Enhancement of Ocular Tissue Penetration. Compared with traditional equipment,1050nm wavelength light source can penetrate deeper into ocular tissues., improve the detection rate of patients with refractive media opacity, and achieve precise acquisition of ocular biometric data.The application of this innovative technology provides reliable imaging support for the preoperative planning of refractive cataracts, assisting doctors in formulating more precise treatment plans, therebyIncrease the success rate of surgery and avoid unexpected refraction issues. This breakthrough technology achievement fully demonstrates Moptim's profound technical accumulation and innovation capabilities in the ophthalmology field.Shenzhen MoptimShenzhen Certainn Technology Co., Ltd. was established in 2003 and is committed to the industrialization of ophthalmic Optical Coherence Tomography (OCT).Moptim focuses onOphthalmic Diagnosis, Ophthalmic Surgery, Refraction ExaminationThree major core细分 fields of ophthalmology, including products such as Optical Coherence Tomography (OCT),Ophthalmic Optical Biometer, Ophthalmic surgical microscope, Slit lamp microscope, Handheld vision screening device,Home Refractometer, intelligent electronic vision charts, etc.▲Company Products (from official WeChat)OCT (Optical Coherence Tomography), as a high-end medical device in ophthalmology, is highly import-dependent and expensive. After years of dedicated research and industrialization exploration,At the end of 2008, Moptim achievedFirstChina-Made OCT Registration Certificate, successfully breaking foreign monopolies, achieving the industrialization of OCT equipment, and becomingThe First in ChinaApproved Ophthalmic OCT Medical Device Companies. Immediately after, Moptim launchedChina's FirstDoppler Vascular Imaging OCT &GlobalThe First Ophthalmic Optical Biometer Based on Frequency Domain OCT Technology。▲Moptim's earliest OCT model, developed in 2003 (from the official website)After more than a decade of industry development, Moptim has become the leader in the field of domestically produced ophthalmic medical devices.Products and solutions have covered more than 8,000 medical institutions worldwide.In recent years, the demand for biometers and myopia prevention and control devices has surged, gradually becoming a strong new growth point for the company.At the same time,Moptim is also actively expanding overseas markets and is one of the earliest ophthalmic medical device companies in China to establish a presence in international markets.. Currently, it hasEstablish sales channels in more than 50 countries and regions, with products spread across Europe, South America, Asia-Pacific and other regions.As a collaborative research and development base of Tsinghua University's Shenzhen Graduate School, the company's technical and talent backbone originates from Tsinghua University. With the united efforts of this high-quality and youthful R&D team, the technology and products have maintained rapid development. The company ranks at an internationally top-tier level in core aspects such as OCT core algorithms and optical design.Since its establishment, Moptim has been closely cooperating and exchanging technology with multiple universities and clinical medical institutions, such as Zhongshan Ophthalmic Center of Sun Yat-sen University, Shenzhen Eye Hospital, and Peking University Shenzhen Hospital. It now owns more than 170 authorized patents, including 11 PCT patents.# Expand AI Ophthalmic Medical Device ServicesOphthalmic diseases are the third largest disease affecting the quality of life, after tumors and cardiovascular/cerebrovascular diseases.. And all along, "difficulty in taking X-rays" and "difficulty in reading X-rays" are traditional grassrootsFundus ScreeningPain points at work. In this environment, the application of AI in the field of ophthalmology is gradually developing, utilizingArtificial Intelligence for Judging Fundus Images, which can quickly screen for fundus diseases, such as common cataracts, diabetic retinopathy, and other retinal diseases,Achieve the effect of early screening, early prevention, and early treatment.。In 2020,Moptim Imaging Collaborates with Ping An Smart City, Moptim has made breakthrough achievements in the fields of early disease screening through intelligent healthcare and AI-assisted diagnosis and treatment, successfully developing"OCT-AI": An Intelligent Ophthalmic OCT Screening System Combining China-Made OCT and AI. This system has four AI functions: OCT image quality control,Retinopathy Screening, Automatic Detection of Retinal Lesions, OCT Image Quality Enhancement.In addition, in February 2023, Moptim announced that it had become one of the first ecosystem partners of Baidu's Wenxin Yiyan (English name: ERNIE Bot). Moptim willApply Baidu's leading intelligent dialogue technology achievements in the field of ophthalmic medical devices.This move marks that Moptim has prioritized access to leading AI technology, and also marksThe First Landing of Conversational Language Model Technology in Ophthalmic Medical Scenarios in China。
